Anthony Marucci, Celldex CEO
Celldex fleshes out case for Xolair challenger in chronic hives
Celldex Therapeutics is detailing more data from a Phase I trial, close to eight months after sharing initial responses from an interim analysis.
The New …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.